Teva Pharmaceuticals announced Feb. 17 that the U.S. Food and Drug Administration approved AUSTEDO XR (deutetrabenazine) extended-release tablets, a once-daily treatment for adults with tardive ...

(RTTNews) - Neurocrine Biosciences Inc. (NBIX) said that it will present new data from its movement disorder treatments for tardive dyskinesia or TD and Parkinson's disease at the International ...

Please provide your email address to receive an email when new articles are posted on . Teva Pharmaceuticals announced FDA approval of Austedo XR, a once-daily, extended-release formulation for adults ...

In 2024, several research and pharmacological advancements were made for tardive dyskinesia, a movement disorder caused by dopamine-blocking medications. Below are some of the highlights of the year.

Ingrezza (valbenazine) is a prescription drug that’s used to treat certain movement disorders. Ingrezza comes as a capsule that you swallow. Specifically, Ingrezza is used to treat these conditions in ...

Ways to make eating and swallowing easier with tardive dyskinesia include switching medications, dietary changes, working with a speech-language pathologist, and more. Tardive dyskinesia (TD) is a ...

SAN DIEGO, Aug. 29, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today presented findings from a data analysis of KINECT ®-4 demonstrating a comparable pattern of ...

Evoke Pharma, Inc. announced that an abstract comparing the incidence of tardive dyskinesia (TD) in patients undergoing continuous versus intermittent oral metoclopramide treatment has been accepted ...

Tardive dyskinesia (TD) can be addressed by the right intervention even in severe, refractory cases. These cases, characterized by involuntary muscle movements, are most often caused by antipsychotics ...

People with movement disorders can have a difficult time doing day-to-day activities, which could impact their independence. This can affect how people see themselves and affect their social life.

DUBLIN, Nov. 20, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2 clinical trial of ...